0.04Open0.04Pre Close0 Volume151 Open Interest7.50Strike Price0.00Turnover531.59%IV362.58%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.0852Delta0.1126Gamma40.75Leverage Ratio-0.0109Theta0.0000Rho3.47Eff Leverage0.0004Vega
Compugen Stock Discussion
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Compugen (NASDAQ: CGEN) has been granted a new U.S. patent (No. 12152084) covering the triple combination use of its COM902 anti-TIGIT antibody with anti-PD-1 and anti-PVRIG antibodies for cancer treatment.
The patent strengthens Compugen's IP portfolio and protects the use of COM902, a reduc...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
No comment yet